B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results

Abstract

Like several other immunotherapeutic approaches tested, in recent-onset T1DM, rituximab delays the fall in C-peptide but does not appear to fundamentally alter the underlying pathophysiology of the disease.